Disclosures for "Opicapone Improved Parkinson’s Disease-related Sleep Disturbances: Findings from the OASIS Study"
-
Prof. Gago has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bial. Prof. Gago has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Prof. Gago has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zambon.
-
Dr. Costa has nothing to disclose.
-
Mr. Fonseca has received personal compensation for serving as an employee of Bial.
-
Dr. Almeida has received personal compensation for serving as an employee of Bial.
-
Dr. Brigas has received personal compensation for serving as an employee of BIAL.
-
Dr. Banisadr has received personal compensation for serving as an employee of Amneal Pharmaceuticals.
-
Francisco Rocha has received personal compensation for serving as an employee of BIAL - Portela.
-
Mr. Holenz has received personal compensation for serving as an employee of BIAL. Mr. Holenz has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for BIAL RD Investments. Mr. Holenz has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for BIAl Portela SA. Mr. Holenz has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for BIAL Biotech . Mr. Holenz has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. Mr. Holenz has stock in Astra Zeneca. Mr. Holenz has received intellectual property interests from a discovery or technology relating to health care.
-
Author has nothing to disclose